Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the medication oxytocin is an effective and
tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially
appropriate behaviors and reducing social anxiety.